{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-281950","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.812147+00:00","generated_at":"2026-06-22T00:24:32.689637+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biogen appoints Christopher Viehbacher as President and CEO effective Nov 14, 2022","bullets":["Viehbacher succeeds Michel Vounatsos, who steps down as CEO and from the Board.","Viehbacher receives $1.6M base salary, 150% target bonus, and initial equity awards totaling $28M (options + PSUs).","He must purchase at least $2M of Biogen stock; then receive an RSU grant of $2M vesting in 3 years.","Severance: 1.5x salary plus target bonus if terminated without cause or for good reason; 2x if change in control.","Viehbacher co-founded Gurnet Point Capital, former global CEO of Sanofi."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-281950","json":"https://secwatch.observer/filing/0001193125-22-281950.json","markdown":"https://secwatch.observer/filing/0001193125-22-281950.md","text":"https://secwatch.observer/filing/0001193125-22-281950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000119312522281950/0001193125-22-281950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000119312522281950/d419645d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:24:32.689637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5d8efed36","claim":"Michel Vounatsos departed as CEO at BIOGEN INC..","evidence_excerpt":"Michel Vounatsos will step down as Biogen’s CEO and will resign from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312522281950/0001193125-22-281950-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"CEO"}],"fact_type":"executive_change"},{"claim_id":"dde5df27fd","claim":"Christopher A. Viehbacher was appointed as President and CEO at BIOGEN INC..","evidence_excerpt":"appointed Christopher A. Viehbacher, age 62, to serve as President and CEO of Biogen, beginning November 14, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312522281950/0001193125-22-281950-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and CEO"}],"fact_type":"executive_change"},{"claim_id":"e6cdf2eb4c","claim":"Christopher A. Viehbacher was appointed as Director at BIOGEN INC..","evidence_excerpt":"Mr. Viehbacher will succeed Michel Vounatsos as director of Biogen effective November 14, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000119312522281950/0001193125-22-281950-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}